Market Cap | 317.62M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -56.93M | Forward P/E | -3.64 | EPS next Y | - | 50D Avg Chg | 8.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 16.00% |
Dividend | N/A | Price/Book | 6.86 | EPS next 5Y | -51.60% | 52W High Chg | -44.00% |
Recommedations | 1.00 | Quick Ratio | 1.76 | Shares Outstanding | 112.91M | 52W Low Chg | 102.00% |
Insider Own | 50.71% | ROA | -48.34% | Shares Float | 55.62M | Beta | 3.05 |
Inst Own | 0.32% | ROE | -150.65% | Shares Shorted/Prior | 4.22M/3.85M | Price | 2.51 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 229,066 | Target Price | 15.00 |
Oper. Margin | - | Earnings Date | Oct 2 | Volume | 61,914 | Change | -4.20% |
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
Baird | Outperform | Sep 8, 23 |
Evercore ISI Group | In-Line | Apr 27, 22 |
Jefferies | Buy | Dec 7, 21 |
B of A Securities | Buy | Dec 6, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Prime Movers Lab Fund I LP | 10% Owner 10% Owner | Sep 06 | Sell | 1.78 | 96,936 | 172,546 | 3,594,122 | 09/08/23 |
Diamandis Peter | Director Director | Apr 26 | Option | 0.89 | 475,537 | 423,228 | 906,141 | 05/02/23 |
Prime Movers Lab Fund I LP | 10% Owner 10% Owner | Jan 23 | Sell | 3.35 | 500,692 | 1,677,318 | 8,764,372 | 01/25/23 |
Prime Movers Lab Fund I LP | 10% Owner 10% Owner | Dec 01 | Sell | 2.77 | 348,548 | 965,478 | 9,169,589 | 12/05/22 |
Prime Movers Lab Fund I LP | 10% Owner 10% Owner | Sep 06 | Sell | 2.4 | 37,358 | 89,659 | 9,451,674 | 09/08/22 |
Guirakhoo Farshad | (Former) Chief Scien.. (Former) Chief Scientific Off. | Jan 13 | Option | 0.57 | 58,645 | 33,428 | 68,645 | 08/29/22 |
Prime Movers Lab Fund I LP | 10% Owner 10% Owner | Aug 23 | Sell | 2.39 | 207,680 | 496,355 | 9,476,917 | 08/25/22 |
Diamandis Peter | Director Director | Nov 18 | Sell | 13 | 248 | 3,224 | 90,499 | 06/23/22 |
Reese Lou | Executive Chairman Executive Chairman | Jun 16 | Buy | 1.9929 | 100,000 | 199,290 | 51,737,344 | 06/21/22 |
Hu Mei Mei | See Remarks See Remarks | Jun 16 | Buy | 1.9929 | 100,000 | 199,290 | 51,737,344 | 06/21/22 |
UNITED BIOMEDICAL INC | 10% Owner 10% Owner | Jun 16 | Buy | 1.9929 | 100,000 | 199,290 | 51,737,344 | 06/21/22 |
Prime Movers Lab Fund I LP | 10% Owner 10% Owner | Jun 10 | Sell | 2.61 | 179,000 | 467,190 | 9,617,245 | 06/14/22 |
UNITED BIOMEDICAL INC | 10% Owner 10% Owner | Jun 08 | Buy | 2.84 | 20,978 | 59,578 | 51,637,344 | 06/10/22 |
Hu Mei Mei | See Remarks See Remarks | Jun 08 | Buy | 2.84 | 20,978 | 59,578 | 51,637,344 | 06/10/22 |
Reese Lou | Executive Chairman Executive Chairman | Jun 08 | Buy | 2.84 | 20,978 | 59,578 | 51,637,344 | 06/10/22 |
Guirakhoo Farshad | Chief Scientific Off.. Chief Scientific Officer | May 03 | Option | 0.57 | 10,000 | 5,700 | 10,000 | 05/05/22 |
UNITED BIOMEDICAL INC | 10% Owner 10% Owner | Apr 26 | Buy | 3.52 | 22,912 | 80,650 | 51,616,366 | 04/28/22 |
Reese Lou | Executive Chairman Executive Chairman | Apr 26 | Buy | 3.52 | 22,912 | 80,650 | 51,616,366 | 04/28/22 |
Hu Mei Mei | See Remarks See Remarks | Apr 26 | Buy | 3.52 | 22,912 | 80,650 | 51,616,366 | 04/28/22 |
Hu Mei Mei | See Remarks See Remarks | Apr 25 | Buy | 3.3681 | 8,038 | 27,073 | 51,593,454 | 04/27/22 |
Reese Lou | Executive Chairman Executive Chairman | Apr 25 | Buy | 3.3681 | 8,038 | 27,073 | 51,593,454 | 04/27/22 |
UNITED BIOMEDICAL INC | 10% Owner 10% Owner | Apr 25 | Buy | 3.3681 | 8,038 | 27,073 | 5,193,454 | 04/27/22 |
Diamandis Peter | Director Director | Jan 24 | Option | 4.1192 | 652,764 | 2,688,865 | 729,687 | 01/26/22 |
Chui James | Director Director | Dec 31 | Buy | 5.48 | 6,000 | 32,880 | 14,000 | 01/06/22 |
Reese Lou | Executive Chairman Executive Chairman | Nov 12 | Buy | 13.82 | 17,500 | 241,850 | 17,500 | 11/15/21 |
Hu Mei Mei | See Remarks See Remarks | Nov 12 | Buy | 13.82 | 17,500 | 241,850 | 17,500 | 11/15/21 |